Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
lung cancer treatment
Jul 1, 2024, 02:31 |
Blog
Biagio Ricciuti receives a 2024 IASLC YIA to develop new therapies for KRAS amplified NSCLC
Biagio Ricciuti shared a post by Dana-Farber News, on X: "Thrilled to receive a 2024…
Jun 29, 2024, 14:04 |
Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 29, 2024, 13:41 |
Societies
ESMOGI24 Key Insights Shared By Megan Barnet
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29…
Jun 28, 2024, 14:34 |
Blog
María Natalia Gandur Quiroga: Imfinzi Shows Significant Survival Benefits in NIAGARA Phase III Trial
María Natalia Gandur Quiroga shared on LinkedIn: . "Imfinzi Shows Significant Survival Benefits in NIAGARA…
Jun 28, 2024, 12:02 |
Blog
Herbert Loong: Regulatory Harmonisation For Oncology Clinical Trials in the APAC Region
Herbert Loong made the following post on LinkedIn: . "A shoutout again to all colleagues…
Jun 28, 2024, 11:08 |
Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 27, 2024, 14:49 |
Societies
ESMOGI24 Presentations Summarized By Megan Barnet
ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…
Jun 26, 2024, 08:30 |
Insight
IMFINZI (durvalumab) showed improved EFS and OS for MIBC in NIAGARA Phase III trial
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results…
Jun 25, 2024, 07:23 |
Blog
Dr. Herbert Loong shared his insights from ASCO24
Herbert Loong shared on LinkedIn: "Dr. Herbert Loong shared his insights on GIST-relevant presentations from the…
Jun 24, 2024, 02:03 |
Opinion
Jill Feldman: We need a shift in the Adverse Event grading system
Jill Feldman shared a post on X: “Just thinking, I strongly advocate changing the dose…
63
64
65
66
67
All:
857
Posts:
641 - 650
Agenus CEO Dr. Garo Armen Honored with WITSA Eminent Person 2024 Award for Cancer Immunotherapy Breakthrough
Vivek Subbiah: Key publications leading to Nobel Prize 2024, published in 1993
Dr. Zainab Shinkafi-Bagudu: Advocating for Equity in Cancer Care - UICC Presidential Candidacy
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 6
ASTRO24: 15 Posts Not To Miss From Day 4
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube